Phase 3 program targeting a potential US$2.2B U.S. market opportunity505(b)(2) regulatory path leveraging prior human data to reduce risk, cost, and timeFDA-reviewed CMC package validated through prior ANDA approvalPatent coverage to 2036 for ketamine in Parkinson's and related motor disordersActive pharmaceutical partnering discussionsUpcoming catalysts (Q4 2025 - Q2 2026): FDA meeting, pivotal study readiness, pharma partnershipToronto, Ontario--(Newsfile Corp. - October 8, 2025) - PharmaTher Holdings Lt ...